A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects

Naoto Kuroda; Emiko Sugawara; Hironori Kusano; Yoshiaki Yuba; Kenji Yorita; Kengo Takeuchi

doi:10.5114/pjp.2018.76693

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2018
vol. 69

Send email

Copy url:

abstract:

Review paper

A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects

Naoto Kuroda

,

Emiko Sugawara

,

Hironori Kusano

,

Yoshiaki Yuba

,

Kenji Yorita

,

Kengo Takeuchi

Pol J Pathol 2018; 69 (2): 109-113

DOI: https://doi.org/10.5114/pjp.2018.76693

Online publish date: 2018/07/06

View full text Get citation

PlumX metrics:

ALK-rearranged renal cell carcinoma (ALK-RCC) has been recently proposed and incorporated into the recent World Health Organisation Classification of renal tumours as a provisional entity. In this article, we review ALK-RCC with a focus on clinical and pathobiological aspects. Seventeen cases have been described to date. ALK-RCC accounts for less than 1% of all renal tumours. The age of patients ranges from 6 to 61 years with a mean age of 29.6 years. Grossly, the tumour forms were ill-demarcated or well demarcated solid mass in the renal medulla. Histologically, RCC with VCL-ALK translocation resembles renal medullary carcinoma and mucinous cribriform pattern, signet-ring cell pattern and solid rhabdoid pattern are often observed in RCC with non-VCL-ALK fusion. Immunohistochemically, ALK protein diffusely expresses and TFE3 is often expressed. ALK gene can fuse to VCL, TPM3, EML4, HOOK1 or STRN gene. A break-apart fluorescence in situ hybridisation study is clinically available for the practice of definite diagnosis. ALK inhibitor therapy will provide great benefit for patients with advanced stage of ALK-RCC in the near future.

keywords:

A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects

Naoto Kuroda , Emiko Sugawara , Hironori Kusano , Yoshiaki Yuba , Kenji Yorita , Kengo Takeuchi

ALK, renal cell carcinoma, pathology, review

Naoto Kuroda

,

Emiko Sugawara

,

Hironori Kusano

,

Yoshiaki Yuba

,

Kenji Yorita

,

Kengo Takeuchi